Abstract
Lebrikizumab (lebri) is a novel, monoclonal antibody that selectively targets interleukin (IL)-13 and prevents formation of the IL-13 receptor alpha 1 (Rα1)/IL-4 receptor alpha (Rα) heterodimer receptor signaling complex. A previous crystal structure report showed that lebri does not interfere with binding of IL-13 to the IL-13 Receptor alpha 2 (Ra2) decoy receptor. In contrast, other IL-13 antibodies tralokinumab and cendakimab had been reported to inhibit IL-13 binding to both IL-13Ra1 and IL-13Ra2.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
